Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomized feasibility study justifying a multicentre phase III trial

R. H. De Boer, I. E. Smith, U. Pastorino, M. E R O'Brien, F. Ramage, S. Ashley, P. Goldstraw

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m-2, vinblastine 6 mg m-2 and cisplatin 50 mg m-2 (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage, none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.

Original languageEnglish
Pages (from-to)1514-1518
Number of pages5
JournalBritish Journal of Cancer
Volume79
Issue number9-10
Publication statusPublished - 1999

Fingerprint

Feasibility Studies
Non-Small Cell Lung Carcinoma
Drug Therapy
Neoplasms
Vinblastine
Mitomycin
Adjuvant Chemotherapy
Cisplatin
Biomedical Research
Cause of Death
Lung Neoplasms
Appointments and Schedules
Survival Rate
Quality of Life
Recurrence
Therapeutics

Keywords

  • Cisplatin
  • Mitomycin-C
  • Non-small-cell lung cancer
  • Pre-operative chemotherapy
  • Vinblastine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer : A randomized feasibility study justifying a multicentre phase III trial. / De Boer, R. H.; Smith, I. E.; Pastorino, U.; O'Brien, M. E R; Ramage, F.; Ashley, S.; Goldstraw, P.

In: British Journal of Cancer, Vol. 79, No. 9-10, 1999, p. 1514-1518.

Research output: Contribution to journalArticle

De Boer, R. H. ; Smith, I. E. ; Pastorino, U. ; O'Brien, M. E R ; Ramage, F. ; Ashley, S. ; Goldstraw, P. / Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer : A randomized feasibility study justifying a multicentre phase III trial. In: British Journal of Cancer. 1999 ; Vol. 79, No. 9-10. pp. 1514-1518.
@article{b0cf5825c7624b06a3feaf1757455275,
title = "Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: A randomized feasibility study justifying a multicentre phase III trial",
abstract = "Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m-2, vinblastine 6 mg m-2 and cisplatin 50 mg m-2 (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55{\%}) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50{\%}) or partial (50{\%}) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27{\%} minor tumour shrinkage, none had progressive disease. Partial pathological response was seen in 50{\%}. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.",
keywords = "Cisplatin, Mitomycin-C, Non-small-cell lung cancer, Pre-operative chemotherapy, Vinblastine",
author = "{De Boer}, {R. H.} and Smith, {I. E.} and U. Pastorino and O'Brien, {M. E R} and F. Ramage and S. Ashley and P. Goldstraw",
year = "1999",
language = "English",
volume = "79",
pages = "1514--1518",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9-10",

}

TY - JOUR

T1 - Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer

T2 - A randomized feasibility study justifying a multicentre phase III trial

AU - De Boer, R. H.

AU - Smith, I. E.

AU - Pastorino, U.

AU - O'Brien, M. E R

AU - Ramage, F.

AU - Ashley, S.

AU - Goldstraw, P.

PY - 1999

Y1 - 1999

N2 - Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m-2, vinblastine 6 mg m-2 and cisplatin 50 mg m-2 (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage, none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.

AB - Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m-2, vinblastine 6 mg m-2 and cisplatin 50 mg m-2 (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage, none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.

KW - Cisplatin

KW - Mitomycin-C

KW - Non-small-cell lung cancer

KW - Pre-operative chemotherapy

KW - Vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0033013285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033013285&partnerID=8YFLogxK

M3 - Article

C2 - 10188899

AN - SCOPUS:0033013285

VL - 79

SP - 1514

EP - 1518

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9-10

ER -